Published in Hospital and Nursing Home Week, September 8th, 2005
Forteo is the first and only U.S. Food and Drug Administration (FDA) approved bone formation agent that actually forms new bone in postmenopausal women with osteoporosis at high risk for fracture. Fosamax is an inhibitor of bone resorption. These data were published in Archives of Internal Medicine.
The study, which provides more in-depth information than previously available about these two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.